Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363921 | 1.00 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29361239 | 0.87 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1249445 | 0.87 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25571855 | 0.87 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31172721 | 0.87 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30592871 | 0.84 | CYP4F2 (0.52) | KDM4ESMN1; SMN2MAPTALDH1A1CA12 | |
| SCHEMBL1823817 | 0.84 | CYP4F2 (0.52) | KDM4ESMN1; SMN2MAPTALDH1A1CA12 | |
| SCHEMBL23530068 | 0.81 | MAPK1 (0.42) | KDM4ESMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL38655981 | 0.81 | CA12 (0.40) | KDM4ESMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL22557407 | 0.81 | L3MBTL1 (0.42) | KDM4ESMN1; SMN2L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4702028-A1 | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702023-A1 | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | disclosed |
| EP-4688771-A1 | NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015349-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| WO-2025245178-A1 | PAK4, CSTF2, OR CSTF2T PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | INNOVO THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3952870-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| CN-111825657-A | Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof | 成都海创药业有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| WO-2020210379-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| CN-111606928-A | Azacyclodiketone compound and preparation method thereof | 维清生物科技(上海)有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-110878096-A | 1, 7-naphthyridine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2020-03-13 | — | — | CN | disclosed |
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| EP-2222675-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | Genentech, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015349-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | CBR1, HCCS, NCOR1 | TUBB4A 3690/4885TUBB 2327/4885TUBA3C 2870/4885 |
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | TUBB4A 1165/4885TUBB 669/4885TUBA3C 310/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | TUBB4A 672/4885TUBB 602/4885TUBA3C 1226/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | TUBB4A 672/4885TUBB 602/4885TUBA3C 1226/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | TUBB4A 862/4885TUBB 782/4885TUBA3C 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.